Publicacións nas que colabora con Purificación Cid Silva (11)

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2021

  1. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 1, pp. 16-21

2020

  1. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

    Journal of Medical Virology, Vol. 92, Núm. 12, pp. 3488-3498

  2. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 1 e, pp. E41-E47

2019

  1. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  2. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  3. Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

    Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406

  4. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

2017

  1. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 5, pp. 442-446